Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1990 1
1996 1
2001 1
2002 1
2003 1
2004 1
2005 1
2008 2
2009 1
2010 1
2011 1
2016 1
2017 1
2019 2
2021 2
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Characterization and treatment of congenital thrombotic thrombocytopenic purpura.
Alwan F, Vendramin C, Liesner R, Clark A, Lester W, Dutt T, Thomas W, Gooding R, Biss T, Watson HG, Cooper N, Rayment R, Cranfield T, van Veen JJ, Hill QA, Davis S, Motwani J, Bhatnagar N, Priddee N, David M, Crowley MP, Alamelu J, Lyall H, Westwood JP, Thomas M, Scully M. Alwan F, et al. Among authors: cranfield t. Blood. 2019 Apr 11;133(15):1644-1651. doi: 10.1182/blood-2018-11-884700. Epub 2019 Feb 15. Blood. 2019. PMID: 30770395 Free article. Review.
Study tips for medical students.
Richmond A, Cranfield T, Cooper N. Richmond A, et al. Among authors: cranfield t. BMJ. 2019 Apr 11;365:k663. doi: 10.1136/bmj.k663. BMJ. 2019. PMID: 30975707 No abstract available.
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.
Russell NH, Wilhelm-Benartzi C, Othman J, Dillon R, Knapper S, Batten LM, Canham J, Hinson EL, Betteridge S, Overgaard UM, Gilkes A, Potter N, Mehta P, Kottaridis P, Cavenagh J, Hemmaway C, Arnold C, Freeman SD, Dennis M; PORTEC Study Group. Russell NH, et al. J Clin Oncol. 2024 Apr 1;42(10):1158-1168. doi: 10.1200/JCO.23.00943. Epub 2024 Jan 12. J Clin Oncol. 2024. PMID: 38215358 Clinical Trial.
Real-world experience with caplacizumab in the management of acute TTP.
Dutt T, Shaw RJ, Stubbs M, Yong J, Bailiff B, Cranfield T, Crowley MP, Desborough M, Eyre TA, Gooding R, Grainger J, Hanley J, Haughton J, Hermans J, Hill Q, Humphrey L, Lowe G, Lyall H, Mohsin M, Nicolson PLR, Priddee N, Rampotas A, Rayment R, Rhodes S, Taylor A, Thomas W, Tomkins O, Van Veen JJ, Lane S, Toh CH, Scully M. Dutt T, et al. Among authors: cranfield t. Blood. 2021 Apr 1;137(13):1731-1740. doi: 10.1182/blood.2020007599. Blood. 2021. PMID: 33150355 Free article.
Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine: Comment from Doyle et al.
Doyle AJ, Springell D, Dutt T, Kenworthy J, Ling G, Desborough M, Thomas W, Hermans J, Vanveen J, Cranfield T, Belsham E, Hill QA, Lester W, Scully M. Doyle AJ, et al. Among authors: cranfield t. J Thromb Haemost. 2022 Mar;20(3):781-783. doi: 10.1111/jth.15632. J Thromb Haemost. 2022. PMID: 35220653 Free PMC article. No abstract available.
Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura.
Alwan F, Vendramin C, Vanhoorelbeke K, Langley K, McDonald V, Austin S, Clark A, Lester W, Gooding R, Biss T, Dutt T, Cooper N, Chapman O, Cranfield T, Douglas K, Watson HG, van Veen JJ, Sibson K, Thomas W, Manson L, Hill QA, Benjamin S, Ellis D, Westwood JP, Thomas M, Scully M. Alwan F, et al. Among authors: cranfield t. Blood. 2017 Jul 27;130(4):466-471. doi: 10.1182/blood-2016-12-758656. Epub 2017 Jun 2. Blood. 2017. PMID: 28576877 Free article. Clinical Trial.
A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
Dennis M, Burnett A, Hills R, Thomas I, Ariti C, Severinsen MT, Hemmaway C, Greaves P, Clark RE, Copland M, Russell N; National Cancer Research Institute (NCRI) acute myeloid leukaemia (AML) Working Group. Dennis M, et al. Br J Haematol. 2021 Jul;194(2):298-308. doi: 10.1111/bjh.17501. Epub 2021 May 7. Br J Haematol. 2021. PMID: 33961292 Clinical Trial.
22 results